Sangamo Appoints CEO
Executive Summary
Sangamo Biosciences, a company focused on treating monogenic and infectious diseases using its DNA-binding protein technology, has appointed Alexander 'Sandy' Macrae president and CEO. Macrae will be succeeding current president and CEO Edward Lanphier, who will be retiring from his leadership position but will continue as board member. Macrae previously held roles of increasing responsibility at SmithKline Beecham and GlaxoSmithKline, where his last role was senior vice president, emerging markets research and development.